SCHEMBL85958

SCHEMBL85958

CCOC(=O)c1cc2cc(C)ccc2n1-c1ccc(OCc2ccccc2)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SRD5A2 P31213 1/20 0.51
MEN1 O00255 3/20 0.47
KMT2A Q03164 3/20 0.47
HSP90AA1 P07900 1/20 0.47
L3MBTL1 Q9Y468 3/20 0.47
NPC1 O15118 3/20 0.47
RAB9A P51151 3/20 0.47
PKM P14618 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
TP53 P04637 1/20 0.46
LMNA P02545 2/20 0.46
MAOB P27338 2/20 0.45
PPARG P37231 1/20 0.45
PLA2G10 O15496 1/20 0.45
NOD2 Q9HC29 1/20 0.45
NOD1 Q9Y239 1/20 0.45
MAPT P10636 1/20 0.44
LTB4R Q15722 1/20 0.44
LTB4R2 Q9NPC1 1/20 0.44
NR1H4 Q96RI1 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL73191 0.91 SRD5A2 (0.53) SRD5A2MEN1KMT2AHSP90AA1L3MBTL1
SCHEMBL3010897 0.86 SRD5A2 (0.53) SRD5A2MEN1KMT2AHSP90AA1L3MBTL1
SCHEMBL17647214 0.84 MAPT (0.51) MEN1KMT2AL3MBTL1NPC1RAB9A
SCHEMBL4925290 0.80 MAPT (0.49) SRD5A2MEN1KMT2AHSP90AA1L3MBTL1
SCHEMBL4920937 0.80 L3MBTL1 (0.50) SRD5A2MEN1KMT2AHSP90AA1L3MBTL1
SCHEMBL8687408 0.79 SRD5A2 (0.76) SRD5A2MEN1KMT2AHSP90AA1L3MBTL1
SCHEMBL85713 0.79 NPC1 (0.48) SRD5A2MEN1KMT2AL3MBTL1NPC1
SCHEMBL3639123 0.78 SRD5A2 (0.61) SRD5A2MEN1KMT2AHSP90AA1L3MBTL1
SCHEMBL15908729 0.78 SRD5A2 (0.61) SRD5A2MEN1KMT2AHSP90AA1L3MBTL1
SCHEMBL85712 0.77 NPC1 (0.48) SRD5A2MEN1KMT2AL3MBTL1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8129424-B2 Indole derivatives as histamine 3 receptor inhibitors for the treatment of cognitive and sleep disorders, obesity and other CNS disorders ATHERSYS, INC. (US) 2012-03-06 US disclosed
US-20110059966-A1 INDOLE DERIVATIVES AS HISTAMINE 3 RECEPTOR INHIBITORS FOR THE TREATMENT OF COGNITIVE AND SLEEP DISORDERS, OBESITY AND OTHER CNS DISORDERS BENNANI YOUSSEF L 2011-03-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110059966-A1 INDOLE DERIVATIVES AS HISTAMINE 3 RECEPTOR INHIBITORS FOR THE TREATMENT OF COGNITIVE AND SLEEP DISORDERS, OBESITY AND OTHER CNS DISORDERS HRH3, HCRTR1, HCRTR2 SRD5A2 2436/4885MEN1 1562/4885KMT2A 139/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.